Phase 4
Completed N=6
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)
Source: ClinicalTrials.gov NCT00367016 ↗Enrolled (actual)
6
Serious AEs
0.0%
Results posted
Jul 2021
Primary outcomePrimary: FcεRI (High Affinity Receptor) Levels at 3 Months — 20.5; 13.66 Positive cells per field
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of this study is to look at measures that will help scientists understand the way Omalizumab, an FDA-approved anti-allergy medication, works.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY FcεRI (High Affinity Receptor) Levels at 3 Months |
20.5; 13.66 | — |
| PRIMARY FcεRI (High Affinity Receptor) Levels at 6 Months |
17; 22.5 | — |
| SECONDARY Total Sera IgE Levels at 6 Months |
300; 883.33 | — |
Eligibility Criteria
Inclusion Criteria
- Mild or moderate persistent asthma
- Allergic rhinitis
- Atopic dermatitis
Exclusion Criteria
- Other lung diseases
- Blood clotting disorder
- Pregnant or lactating women
Data sourced from ClinicalTrials.gov (NCT00367016). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.